Effect of cytochrome P450 (CYP) 3A4*1G polymorphism on tacrolimus pharmacokinetics, CYP3A5 mRNA expression level and probability of acute cellular rejection.

Trial Profile

Effect of cytochrome P450 (CYP) 3A4*1G polymorphism on tacrolimus pharmacokinetics, CYP3A5 mRNA expression level and probability of acute cellular rejection.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Pharmacokinetics
  • Most Recent Events

    • 28 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top